Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on September 19, 2025
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and …
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre- …
Smart Trading Ecosystem Leading the Industry - Soup Capital Exchange Officially Launches
Denver, CO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Soup Capital LTD has officially announced the launch of its new digital asset trading platform, Soup Capital Exchange. Positioned as a "smart trading ecosystem leading the industry," the platform is set to …
NTA Implant: Solidifying Global Leadership with MDR Certification and Launching a New Era in Implantology
EGOLZWIL, Switzerland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- NTA Implant, a leading brand of the Switzerland-based Pilatus Swiss Dental GmbH, has announced a strategic milestone in its global growth journey by successfully completing the rigorous MDR (Medical …
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated …
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to market neffy in Japan, …
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tablets in Japan, has …
Nuvini Group CEO Pierre Schurmann to Participate in Keynote Presentation at Brazil Investment Week in London on September 30, 2025
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading technology conglomerate in the Latin American SaaS sector, today announced that Chief Executive Officer Pierre Schurmann will …
Iterum Therapeutics Provides Business Update
DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community …
Platinum Analytics Cayman Limited Announces Pricing of Its Initial Public Offering
Singapore, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Platinum Analytics Cayman Limited (the “Company” or “PLTS”), a software developer specializing in the provision of FX trading software development solutions, data analytics solutions and technology development …
Spectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today …
GBT Technologies Announced Non- Binding Offer to Acquire Two Hands Corporation; Builds on Merchant Banking Strategy as Wertheim & Company
WEST HOLLYWOOD, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC Pink: (GTCH) (“GBT or the “Company”) today announced that its Board of Directors has authorized a non-binding indication of interest to acquire all of the issued and …
Vaxart Announces Withdrawal of Reverse Stock Split Proposal
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, …
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories …
NovaQuant Agency Announces Launch of AlphaSynth System Investment Platform and Issuance of NQA Token
Denver, CO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- NovaQuant Agency has officially announced the launch of its AlphaSynth System investment platform together with the issuance of its native digital asset, the NQA Token, marking a significant milestone in the …
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young …
Bylvay® (odévixibat) approuvé au Japon pour le traitement d’une maladie rare du foie (CIFP)
Bylvay® est le premier inhibiteur du transport iléal des acides biliaires administré une fois par jour à être approuvé comme traitement du prurit associé à la cholestase intra-hépatique familiale progressive (CIFP) au Japon, offrant une option de …
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in …
Statement from Bart Demosky, Executive Vice President and Chief Financial Officer, on Daniel Desjardins, Senior Director, Global Risk Management and Insurance, Receiving the Risk and Insurance Management Society’s Donald M. Stuart Award
MONTREAL, Sept. 19, 2025 (GLOBE NEWSWIRE) -- In his role as Senior Director, Global Risk Management and Insurance at Bombardier, Daniel Desjardins has shaped the risk management and insurance landscape, as well as Bombardier’s journey, in profound ways. …